GPCR

Announcements

Nothing here yet

Daily updates

• Structure reported clinical progress across its oral obesity drug portfolioSep 8, 2026

FDA designations

Nothing here yet

News

• Structure Therapeutics reported positive Phase 2 ACCESS II results for once-daily oral GLP-1 receptor agonist aleniglipronMar 16, 2026
• Structure Therapeutics initiates Phase 1 study of ACCG-2671 oral amylin agonist for obesityDec 17, 2025
• Structure Therapeutics reports positive topline data from ACCESS program for once-daily oral GLP-1 agonist AleniglipronDec 8, 2025